Amrita Krishnan1, Stephen J Forman. 1. Division of Hematology/Hematopoietic Stem Cell Transplant, City of Hope Cancer Center, Duarte, California, USA. akrishnan@coh.org
Abstract
PURPOSE OF REVIEW: AIDS-related malignancies are an ongoing cause of mortality in individuals with HIV infection. In the HIV-negative setting, high-dose chemotherapy or stem cell transplantation is an option for patients with hematologic malignancies. Prior to the advent of effective HIV therapy, stem cell transplantation was not feasible for HIV-positive patients. The purpose of this article is to explore the transplant options for HIV-positive patients after widespread use of highly active antiretroviral therapy. RECENT FINDINGS: Early autologous stem cell transplantation has studies had high relapse rates but they demonstrated that mobilization and engraftment of autologous stem cells were possible in AIDS patients. Recently, in less advanced AIDS lymphoma, autologous stem cell transplantation has resulted in low transplant-related mortality and durable remissions. In addition, case-control studies of HIV-positive versus HIV-negative lymphoma patients undergoing autologous stem cell transplantation have shown similar transplant-related mortality and overall survival. The feasibility of allogeneic stem cell transplantation in HIV-infected individuals is less tested. There are challenges of drug interactions between highly active antiretroviral therapy and immunosuppressive agents as well as the potential for higher infection rates. SUMMARY: The potential future applications of autologous and allogeneic stem cell transplantation are the cure of the malignancy as well as the underlying HIV infection by either transplantation of naturally resistant or genetically modified stem cells.
PURPOSE OF REVIEW: AIDS-related malignancies are an ongoing cause of mortality in individuals with HIV infection. In the HIV-negative setting, high-dose chemotherapy or stem cell transplantation is an option for patients with hematologic malignancies. Prior to the advent of effective HIV therapy, stem cell transplantation was not feasible for HIV-positivepatients. The purpose of this article is to explore the transplant options for HIV-positivepatients after widespread use of highly active antiretroviral therapy. RECENT FINDINGS: Early autologous stem cell transplantation has studies had high relapse rates but they demonstrated that mobilization and engraftment of autologous stem cells were possible in AIDSpatients. Recently, in less advanced AIDS lymphoma, autologous stem cell transplantation has resulted in low transplant-related mortality and durable remissions. In addition, case-control studies of HIV-positive versus HIV-negative lymphomapatients undergoing autologous stem cell transplantation have shown similar transplant-related mortality and overall survival. The feasibility of allogeneic stem cell transplantation in HIV-infected individuals is less tested. There are challenges of drug interactions between highly active antiretroviral therapy and immunosuppressive agents as well as the potential for higher infection rates. SUMMARY: The potential future applications of autologous and allogeneic stem cell transplantation are the cure of the malignancy as well as the underlying HIV infection by either transplantation of naturally resistant or genetically modified stem cells.
Authors: François Boué; Jean Gabarre; Christian Gisselbrecht; Jacques Reynes; Antoine Cheret; Fabrice Bonnet; Eric Billaud; Martine Raphael; Remi Lancar; Dominique Costagliola Journal: J Clin Oncol Date: 2006-08-08 Impact factor: 44.544
Authors: J Gabarre; V Leblond; L Sutton; N Azar; M Jouan; C Boccaccio; H Gonzalez; F Charlotte; M Gentilini; J L Binet Journal: Bone Marrow Transplant Date: 1996-12 Impact factor: 5.483
Authors: M Dean; L P Jacobson; G McFarlane; J B Margolick; F J Jenkins; O M Howard; H F Dong; J J Goedert; S Buchbinder; E Gomperts; D Vlahov; J J Oppenheim; S J O'Brien; M Carrington Journal: Cancer Res Date: 1999-08-01 Impact factor: 12.701
Authors: F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg Journal: N Engl J Med Date: 1998-03-26 Impact factor: 91.245
Authors: Amrita Krishnan; Arturo Molina; John Zaia; David Smith; Debbie Vasquez; Neil Kogut; Peter M Falk; Joseph Rosenthal; Joseph Alvarnas; Stephen J Forman Journal: Blood Date: 2004-09-23 Impact factor: 22.113
Authors: A M Levine; J Sullivan-Halley; M C Pike; M U Rarick; C Loureiro; M Bernstein-Singer; E Willson; R Brynes; J Parker; S Rasheed Journal: Cancer Date: 1991-12-01 Impact factor: 6.860
Authors: C A Keever; T N Small; N Flomenberg; G Heller; K Pekle; P Black; A Pecora; A Gillio; N A Kernan; R J O'Reilly Journal: Blood Date: 1989-04 Impact factor: 22.113
Authors: Lawrence D Petz; Istvan Redei; Yvonne Bryson; Donna Regan; Joanne Kurtzberg; Elizabeth Shpall; Jonathan Gutman; Sergio Querol; Pamela Clark; Richard Tonai; Sarah Santos; Aide Bravo; Stephen Spellman; Loren Gragert; John Rossi; Shirley Li; Haitang Li; David Senitzer; John Zaia; Joseph Rosenthal; Stephen Forman; Robert Chow Journal: Biol Blood Marrow Transplant Date: 2012-10-23 Impact factor: 5.742